Vol 71, No 3 (2022)

Introduction. Rheumatoid arthritis is one of the most common autoimmune systemic connective tissue diseases of unknown etiology. Prescribing glucocorticosteroids to patients is associated with loss of bone mass and an increased risk of osteoporosis and osteoporotic fractures. The issues of medical and social significance, clinical and pathogenetic aspects of the development and progression of secondary osteoporosis in rheumatoid arthritis patients need further discussion. Objective. To study medical and social significance, clinical and pathogenetic aspects of secondary osteoporosis in patients with rheumatoid arthritis, questions of complications prevention, including Osteomed, Osteomed Forte, Osteo-Vit D3 prescription. Material and methods. Analysis of 17 Russian and 26 foreign publications, devoted to the problem of the secondary osteoporosis in patients with rheumatoid arthritis, complex prevention of complications, osteoporosis fractures, including Osteomed, Osteomed Forte, Osteo-Bit D3 prescription. Results. It was shown that patients with secondary osteoporosis and rheumatoid arthritis taking Osteomed, Osteomed Forte, Osteo Vit D3 as opposed to patients who didn't get the mentioned preparations had a decreased intensity of pain syndrome, a rate of bone tissue resorption, increased serum calcium concentration, mineral density of bone tissue, improved scores of quality of life. Conclusion. Prescription of Osteomed, Osteomed Forte, Osteo Vit D3 can be recommended in real clinical practice in patients with secondary osteoporosis and rheumatoid arthritis with the account of the personalized approach while choosing the treatment tactics.

Introduction. The development of new herbal medicinal products requires a constant expansion of the raw material base with both new non-pharmacopoeial medicinal plants and nontraditional morphological groups of raw materials of already highly researched species. The introduction of such herbal substances into medical practice requires their standardization so that it can be possible to obtain and sell herbal medicinal products based on that substances. Thus, this necessitates the development of Product specification files. Objective: to study the microdiagnostic traits of sea buckthorn leaves to complete the section “Microscopy” in the draft of pharmacopoeial monograph for these types of herbal substances. Material and methods. The object of the study is the dried leaves of sea buckthorn (Hippophaё rhamnoides L.) harvested on the territory of the Voronezh region (Ostrogozhsky district) during the period of technical maturity of the fruits. Harvesting and drying of leaves was carried out in accordance with the general pharmacopoeial monograph “Leaves”. Sample preparation of raw materials was carried out using various techniques. Microscopy was carried out according to the general pharmacopoeial monograph “Techniques of microscopic and microchemical research of herbal substances and herbal medicinal products” of State Pharmacopeia (XIV edition) of the Russian Federation by light microscopy on a Biomed 6 microscope (Russia) using a Livenhuk C310 NG video camera (PRC) and Top View software (x86). Results. The main microdiagnostic traits of whole leaves of sea buckthorn have been revealed (reticulated venation; 3 types of trichomas: scutellate, stellate and scutellate-stellate; anomocytic type of stomatal complex (on the underside of the leaf); polygonal cells of the epidermis on the upside and cells of the epidermis with strongly branched walls on the underside of the leaf). Biometric characteristics of the main microdiagnostic traits are also determined. Conclusion. Optimal methods of microscopic examination of sea buckthorn leaves have been selected. Anatomical and diagnostic traits of sea buckthorn whole dried leaves also were established.

Introduction. One of the key points in the manufacture of aqueous extracts (infusions and decoctions) is the volume of the extractant used for extraction. Since the dried medicinal plant raw material retains part of the water, it is necessary initially to take more water to obtain the required volume of water extraction, taking into account the water absorption coefficients. The values of the water absorption coefficients are given in the main regulatory document governing the manufacture of drugs in pharmacies - order of the Ministry of Health of the Russian Federation No.751n of 2015. However, in the order, the coefficients are given only for a limited range of medicinal plants. If there is no water absorption coefficient, the order gives recommendations to use the averaged values of the coefficients, which, of course, can lead to a mistakes in the volume and quality of water extracts. Objective: to establish the water absorption coefficients for some types of medicinal plant raw materials for their subsequent use in the manufacture of aqueous extracts in practical pharmacy, as well as in the educational process of educational institutions of the pharmaceutical profile. Material and methods. The objects of the study were Herba Poligoni avicularis, Herba Meliloti, Rhizomata et radices Inulae, Styli cum stigmatis Zeae maydis, Fructus Alni, Folia Betulae, Fructus Juniperi communis that meet the requirements of regulatory documents. Determination of water absorption coefficients was carried out in accordance with the methodology of General Pharmacopoeia Monograph 1.5.3.0012.15. Aqueous extracts were prepared in accordance with GPM.1.4.1.0018.15 “Infusions and decoctions”. Results. The water absorption coefficients were experimentally established for the Herba Poligoni avicularis, Herba Meliloti, Rhizomata et radices Inulae, Styli cum stigmatis Zeae maydis, Fructus Alni, Folia Betulae, Fructus Juniperi communis. It was proved that in the manufacture of water extracts, taking into account the established water absorption coefficients, the volume of the obtained water extraction fits into the norms of permissible deviations. Conclusion. For the studied medicinal plants, the water absorption coefficients were experimentally established, which allow to more correctly calculate the volume of the extractant when obtaining aqueous extracts.

Introduction. In accordance with the principles described in ICH Q8 guideline, the critical characteristics of the components of a dosage form that can affect its quality should be studied before the serial production of a drug. Such parameters include technological properties and biopharmaceutical solubility of an active pharmaceutical ingredient. Objective: to investigate the technological properties and biopharmaceutical solubility of the original substance of a phenyltetrahydroquinolinedione derivative - TRPA1 antagonist in order to develop a solid dosage form based on it. Material and methods. Flowability and angle of repose were determined using an Erweka GTL flow tester. The bulk volume before and after compaction was determined using an ETD-1020 bulk density tester. Equilibrium biopharmaceutical solubility was determined using dissolution tester DT 626/1000 HH. The dissolved quantity of the substance was determined using Agilent 8453 UV spectrophotometer. Results. The flowability was 18.68±1.15 g/s (25 mm funnel); the angle of repose was 46.37±2.04°, the compressibility index and the Hausner ratio were 31.83±1,33% and 1.47±0,09 units, respectively. The calculated therapeutic dose did not completely dissolve in 250 ml of the medium at any pH value. The biopharmaceutical solubility at pH 1.2 was 26.64±1.36 |ig/ml, at pH 4.5 - 2.72±0.15 |ig/ml, at pH 6.8 - 3.8±0.21 |ig/ml. Conclusion. According to the results the following conclusions can be made: it is necessary to use the granulation method or to use the excipients for direct compression; the dissolution profile of the substance allows us to attribute it to class II or IV of the biopharmaceutical classification system, so the development of the dosage form of this substance should be aimed at increasing its solubility or solubility and permeability.

Introduction. Nowadays, in the arsenal of urologists there are special preparations of the gonadotrofic effect of a chemical nature existing, but preparations of plant origin will in many cases be more preferable for stimulation of spermatogenesis and sex steroid production. In this work, the gonadotropic effect of plant Ferula assa-foetida was revealed for the first time. It was proven that the drug action was not centrally stimulating. Objective: to study the gonadotropic action of plant Ferula assa-foetida. Material and methods. The work was carried out on 25 immature (four-month old) mongrel male rats weighing 70-90 grams. The rats were divided into 5 groups, 5 rats in each group. The first group was intact and received water in an appropriate volume. The second group received Menotrophin at a dose of 7 units per body weight. The third group received Menotrophin at a dose of 14 units per body weight. The fourth group received plant Ferula assa-foetida at a dose of 100 mg/kg orally for 7 days before the experiment + 28 units per body weight of Menotrophin. The fifth group - control, this group of animals was administered plant Ferula assa-foetida, orally at a dose of 100 mg/kg for 7 days before the experiment. Results. The tests carried out in the experiment showed that plant Ferula assa-foetida in the dose of 100 mg/kg did not have any centrally stimulating gonadotropic action in comparison with the intact group. Conclusion. Thus, due to the absence of central gonadotropic action of the plant Ferula assa-foetida will not affect the synthesis of two hormones of the anterior pituitary lobe: luteinizing and follicle stimulating hormones, which in turn will prevent such conditions as premature menopause, ovarian hypofunction, precocious puberty, hyperfunction or pituitary tumors.